Drug Trial Radar · NCT06491446
Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
141
Actual
Start
Mar 27, 2024
Primary completion
Oct 17, 2025
Study completion Apr 20, 2026
Sponsor
- Lead sponsor
- Antiva BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Jul 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 25 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a blinded study to assess safety, tolerability, and efficacy of ABI-2280 vaginal inserts in participants diagnosed with persistent cervical hrHPV infection. This study will have up to 11 cohorts with various dose strengths and regimens. Each cohort will start with a sentinel cohort of 8 participants. Sentinel cohorts may be expanded to include an additional up to 32 participants to provide additional proof of concept data to further understanding of benefit/risk of a given dose/dose regimen.
Conditions
- Human Papillomavirus Infection
Interventions
ABI-2280Drug
Different strength of ABI 2280 will be administered in different cohorts. Other: Placebo Matching placebo will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- For sentinel cohorts: Incidence and Severity of Adverse EventsTime frame: Week 24
- For fully expanded cohorts, including sentinel: Clearance of persistent cervical hrHPV infection as defined by the absence of all hrHPV genotypes present at baselineTime frame: Week 12
Locations
24 sites in 4 countries. Site status is shown where the registry gives one.
Emeritus Research Camberwell
Camberwell, Australia
Holdsworth House Medical Practice
Darlinghurst, Australia
KIMR
Nedlands, Australia
The Royal Women's Hospital
Parkville, Australia
Emeritus Research Sydney
Sydney, Australia
AusTrials Taringa
Taringa, Australia
AusTrials Wellers Hill
Tarragindi, Australia
PARC Clinical Research, Royal Adelaide Hospital
Adelaide, South Australia, Australia
International Cancer Institute
Eldoret, Kenya
Victoria Cancer Care & Research Centres
Kisii, Kenya
Kenya Medical Research Institute (KEMRI) - RCTP Kisumu
Kisumu, Kenya
Victoria Biomedical Research Institute
Kisumu, Kenya
Arke Estudios Clinicos S.A. De C.V.
Cuauhtémoc, Mexico
Centro Oncologico Internacional
Mexico City, Mexico
Unidad de Medicina Especializada SMA
Querétaro, Mexico
FAICIC S. de R.L. de C.V.
Veracruz, Mexico
Waitemata Clinical Research Ltd
Birkenhead, New Zealand
P3 Research Dunedin
Dunedin, New Zealand
P3 Research Hawke's Bay
Hastings, New Zealand
P3 Research Lower Hutt
Lower Hutt, New Zealand
Pacific Clinical Trials Network - Tasman
Nelson, New Zealand
P3 Research Kapiti
Paraparaumu, New Zealand
Lakeland Clinical Trials
Rotorua, New Zealand
Clinical Horizons New Zealand
Tauranga, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.